Pharma Deals Review, Vol 2007, No 90 (2007)

Font Size:  Small  Medium  Large

GlaxoSmithKline Gains Antibody for Type I Diabetes

Business Review Editor

Abstract


GlaxoSmithKline and Tolerx entered into license agreement for Tolerx’s otelixizumab (TRX4) monoclonal antibody for treating type I diabetes. The deal would worth up to US$70 M to Tolerx.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.